Results 41 to 50 of about 204,987 (288)
Journal of Medical Case Reports, 2018 Background Novel immune checkpoint inhibitors have been often utilized for different types of malignancies as salvage therapy with varying success. One obstacle to immune checkpoint inhibitor use is the higher incidence of immune-mediated side effects ...
Linh Ngo +3 more
doaj +1 more source
Avelumab-Induced Scleroderma in a Patient with Metastatic Squamous Cell Carcinoma of the Lung
Case Reports in Dermatological Medicine, 2022 Immune checkpoint inhibitors are associated with a spectrum of cutaneous immune-related adverse events. While maculopapular eruptions are the most common cutaneous adverse event, scleroderma can rarely develop.
Jeffrey L. Dobrzynski +2 more
doaj +1 more source
Zhongliu Fangzhi Yanjiu, 2021 Objective To systematically evaluate the efficacy and safety of immune checkpoint inhibitors in the treatment of advanced gastric cancer or gastroesophageal junction cancer (GC/GEJC).
SHAN Yujie +5 more
doaj +1 more source
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy [PDF]
, 2017 Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptors, are targets for monoclonal antibodies (MAbs) developed for cancer immunotherapy.
Mai, Antonello +3 more
core +1 more source
CD8+ T-cell responses in vaccination: Reconsidering targets and function in the context of chronic antigen stimulation [PDF]
, 2018 Cytotoxic CD8 T cells play important roles in eliminating infected and transformed cells. Owing to their potential for therapeutic applications, significant efforts are dedicated toward developing CD8 T cell-based vaccines.
Cosma, Gabriela L., Eisenlohr, Laurence
core +2 more sources
Respirology Case ReportsSeveral predictive factors of immune checkpoint inhibitor response have been reported, but there has not been sufficient exploration of which patients benefit from immune checkpoint inhibitor rechallenge.
Toshiaki Takakura +7 more
doaj +1 more source
Respiratory Medicine Case Reports, 2019 Immune checkpoint inhibitors are known to cause a variety of immune-related adverse events, including pneumonitis. When symptomatic, treatment typically consists of temporary or permanent cessation of the checkpoint inhibitor and several weeks of ...
Camille R. Petri +4 more
doaj +1 more source
Neurological complications of immune checkpoint inhibitors: what happens when you \u27take the brakes off\u27 the immune system. [PDF]
, 2018 Patients with advanced malignancies treated with immune checkpoint inhibitors are at increased risk for developing immune-related neurological complications.
Dalakas, Marinos
core +1 more source
PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy [PDF]
, 2017 Pancreatic ductal adenocarcinoma (PDAC) is considered a non‐immunogenic tumor, and immune checkpoint inhibitor monotherapy lacks efficacy in this disease. Radiotherapy (RT) can stimulate the immune system.
Azad, Abul +11 more
core +1 more source
Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. [PDF]
, 2020 Chemotherapy and checkpoint inhibitor immunotherapies are increasingly used in combinations. We determined associations between the presence of anti-PD-1/PD-L1 therapeutic biomarkers and protein markers of potential chemotherapy response.
Arguello, David +5 more
core +2 more sources